Cardiology

Heart Failure: Targeting the right patients for CRT-D

Patients with dyssynchronous yet viable ventricles are most likely to benefit from cardiac resynchronization therapy combined with defibrillation, concludes the latest analysis of the MADIT CRT trial. The CRT-MADIT-CRT trial ...

Cardiology

New heart failure device is approved

(HealthDay)—The Optimizer Smart System has been approved by the U.S. Food and Drug Administration for people with chronic, moderate-to-severe heart failure who are not candidates for other heart failure remedies.

page 1 from 7